Viral gene therapy for breast cancer: progress and challenges

References

• Lundstrom K, Boulikas T. Viral and non-viral vectors in gene therapy: technology development and clinical trials. Technol Cancer Res Treat. 2003 Oct;2(5):471–486.
   PubMed Web of Science ®Google Scholar
• McCrudden CM, McCarthy HO. Current status of gene therapy for breast cancer: progress and challenges. Appl Clin Genet. 2014;7:209–220.
   PubMedGoogle Scholar
• Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001 Feb 15;409(6822):860–921.
   PubMed Web of Science ®Google Scholar
• Lodish H, Berk A, Zipursky SL. 24.2, proto-oncogenes and tumor-suppressor genes. In: Freeman WH. editor. Molecular cell biology. 4th ed. Freeman WH and Company. New York; 2000.
   Google Scholar
• Schirrmacher V. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol Immunother. 2005 Jun;54(6):587–598.
   PubMed Web of Science ®Google Scholar
• Scholl SM, Balloul JM, Le Goc G, et al. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunotherapy. 2000 Sep-Oct;23(5):570–580.
   PubMed Web of Science ®Google Scholar
• Sadeghi H, Hitt MM. Transcriptionally targeted adenovirus vectors. Curr Gene Ther. 2005 Aug;5(4):411–427.
   PubMed Web of Science ®Google Scholar
• Short JJ, Curiel DT. Oncolytic adenoviruses targeted to cancer stem cells. Mol Cancer Ther. 2009 Aug;8(8):2096–2102.
   PubMed Web of Science ®Google Scholar
• Ribacka C, Pesonen S, Hemminki A. Cancer, stem cells, and oncolytic viruses. Ann Med. 2008;40(7):496–505.
   PubMed Web of Science ®Google Scholar
• Vorburger SA, Hunt KK. Adenoviral gene therapy. Oncologist. 2002;7(1):46–59.
   PubMed Web of Science ®Google Scholar
• Jounaidi Y, Doloff JC, Waxman DJ. Conditionally replicating adenoviruses for cancer treatment. Curr Cancer Drug Targets. 2007 May;7(3):285–301.
   PubMed Web of Science ®Google Scholar
• Hartman ZC, Wei J, Osada T, et al. An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicity and enhanced therapeutic efficacy without oncogenicity. Clin Cancer Res. 2010 Mar 1;16(5):1466–1477.
   PubMed Web of Science ®Google Scholar
• Gyorffy S, Palmer K, Podor TJ, et al. Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL-12: a role for combined anti-angiogenesis and immunotherapy. J Immunol. 2001 May 15;166(10):6212–6217.
   PubMed Web of Science ®Google Scholar
• Ealovega MW, McGinnis PK, Sumantran VN, et al. Bcl-xS gene therapy induces apoptosis of human mammary tumors in nude mice. Cancer Res. 1996 May 1;56(9):1965–1969.
   PubMed Web of Science ®Google Scholar
• Zou Y, Peng H, Zhou B, et al. Systemic tumor suppression by the proapoptotic gene bik. Cancer Res. 2002 Jan 1;62(1):8–12.
   PubMed Web of Science ®Google Scholar
• Huard J, Lochmuller H, Acsadi G, et al. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Therapy. 1995 Mar;2(2):107–115.
   PubMed Web of Science ®Google Scholar
• Worth LL, Jia SF, Zhou Z, et al. Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases. Clin Cancer Res. 2000 Sep;6(9):3713–3718.
   PubMed Web of Science ®Google Scholar
• Gyorffy S, Palmer K, Gauldie J. Adenoviral vector expressing murine angiostatin inhibits a model of breast cancer metastatic growth in the lungs of mice. Am J Pathol. 2001 Sep;159(3):1137–1147.
   PubMed Web of Science ®Google Scholar
• Wold WS, Toth K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther. 2013 Dec;13(6):421–433.
   PubMed Web of Science ®Google Scholar
• Ehrke-Schulz E, Zhang W, Schiwon M, et al. Cloning and large-scale production of high-capacity adenoviral vectors based on the human adenovirus type 5. J Vis Exp. 2016 Jan;28(107):e52894.
   Google Scholar
• Wang L, Hernandez-Alcoceba R, Shankar V, et al. Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer. Gastroenterology. 2004 Jan;126(1):278–289.
   PubMed Web of Science ®Google Scholar
• Wang N, Lu Y, Pinard M, et al. Sustained production of a soluble IGF-I receptor by gutless adenovirus-transduced host cells protects from tumor growth in the liver. Cancer Gene Ther. 2013 Apr;20(4):229–236.
   PubMed Web of Science ®Google Scholar
• Russell SJ. Replicating vectors for cancer therapy: a question of strategy. Semin Cancer Biol. 1994 Dec;5(6):437–443.
   PubMed Web of Science ®Google Scholar
• Rein DT, Breidenbach M, Curiel DT. Current developments in adenovirus-based cancer gene therapy. Future Oncol. 2006 Feb;2(1):137–143.
   PubMedGoogle Scholar
• Liu TC, Kirn D. Gene therapy progress and prospects cancer: oncolytic viruses. Gene Therapy. 2008 Jun;15(12):877–884.
   PubMed Web of Science ®Google Scholar
• Cervantes-Garcia D, Ortiz-Lopez R, Mayek-Perez N, et al. Oncolytic virotherapy. Ann Hepatol. 2008 Jan–Mar;7(1):34–45.
   PubMed Web of Science ®Google Scholar
• Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012 Jul 10;30(7):658–670.
   PubMed Web of Science ®Google Scholar
• Tysome JR, Briat A, Alusi G, et al. Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. Gene Therapy. 2009 Oct;16(10):1223–1233.
   PubMed Web of Science ®Google Scholar
• Yang Y, Xu W, Neill T, et al. Systemic delivery of an oncolytic adenovirus expressing decorin for the treatment of breast cancer bone metastases. Hum Gene Ther. 2015 Dec;26(12):813–825.
   PubMed Web of Science ®Google Scholar
• Zhu W, Wei L, Zhang H, et al. Oncolytic adenovirus armed with IL-24 inhibits the growth of breast cancer in vitro and in vivo. J Exp Clin Cancer Res. 2012 May 28;31:51.
   PubMed Web of Science ®Google Scholar
• Gomes EM, Rodrigues MS, Phadke AP, et al. Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells. Clin Cancer Res. 2009 Feb 15;15(4):1317–1325.
   PubMed Web of Science ®Google Scholar
• Bramante S, Koski A, Liikanen I, et al. Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer. Oncoimmunology. 2016;5(2:e1078057.
   Web of Science ®Google Scholar
• Santiago-Ortiz JL, Schaffer DV. Adeno-associated virus (AAV) vectors in cancer gene therapy. J Control Release. 2016 Oct;28(240):287–301.
   Web of Science ®Google Scholar
• Li C, Bowles DE, van Dyke T, et al. Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther. 2005 Dec;12(12):913–925.
   PubMed Web of Science ®Google Scholar
• Alam S, Bowser BS, Israr M, et al. Adeno-associated virus type 2 infection of nude mouse human breast cancer xenograft induces necrotic death and inhibits tumor growth. Cancer Biol Ther. 2014 Aug;15(8):1013–1028.
   PubMed Web of Science ®Google Scholar
• Subramanian IV, Devineni S, Ghebre R, et al. AAV-P125A-endostatin and paclitaxel treatment increases endoreduplication in endothelial cells and inhibits metastasis of breast cancer. Gene Therapy. 2011 Feb;18(2):145–154.
   PubMed Web of Science ®Google Scholar
• Zhang X, Chen Z, Chen Y, et al. Delivering antisense telomerase RNA by a hybrid adenovirus/adeno-associated virus significantly suppresses the malignant phenotype and enhances cell apoptosis of human breast cancer cells. Oncogene. 2003 Apr 24;22(16):2405–2416.
   PubMed Web of Science ®Google Scholar
• Trepel M, Korbelin J, Spies E, et al. Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors. Gene Therapy. 2015 Oct;22(10):840–847.
   PubMed Web of Science ®Google Scholar
• Luo J, Y L, Sun J, et al. Adeno-associated virus-mediated cancer gene therapy: current status. Cancer Lett. 2015 Jan 28;356(2 Pt B):347–356.
   PubMed Web of Science ®Google Scholar
• Michelfelder S, Kohlschutter J, Skorupa A, et al. Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries. PLoS One. 2009;4(4):e5122.
   PubMed Web of Science ®Google Scholar
• Xu D, McCarty D, Fernandes A, et al. Delivery of MDR1 small interfering RNA by self-complementary recombinant adeno-associated virus vector. Mol Ther. 2005 Apr;11(4):523–530.
   PubMed Web of Science ®Google Scholar
• Xu R, Sun X, Tse LY, et al. Long-term expression of angiostatin suppresses metastatic liver cancer in mice. Hepatology. 2003 Jun;37(6):1451–1460.
   PubMed Web of Science ®Google Scholar
• Ma HI, Guo P, Li J, et al. Suppression of intracranial human glioma growth after intramuscular administration of an adeno-associated viral vector expressing angiostatin. Cancer Res. 2002 Feb 01;62(3):756–763.
   PubMed Web of Science ®Google Scholar
• Davidoff AM, Nathwani AC, Spurbeck WW, et al. rAAV-mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice. Cancer Res. 2002 Jun 1;62(11):3077–3083.
   PubMed Web of Science ®Google Scholar
• Shi W, Teschendorf C, Muzyczka N, et al. Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Ther. 2002 Jun;9(6):513–521.
   PubMed Web of Science ®Google Scholar
• Lalani AS, Chang B, Lin J, et al. Anti-tumor efficacy of human angiostatin using liver-mediated adeno-associated virus gene therapy. Mol Ther. 2004 Jan;9(1):56–66.
   PubMed Web of Science ®Google Scholar
• Cooray S, Howe SJ, Thrasher AJ. Retrovirus and lentivirus vector design and methods of cell conditioning. Methods Enzymol. 2012;507:29–57.
   PubMed Web of Science ®Google Scholar
• Palu G, Parolin C, Takeuchi Y, et al. Progress with retroviral gene vectors. Rev Med Virol. 2000 May–Jun;10(3):185–202.
   PubMed Web of Science ®Google Scholar
• Sakuma T, Barry MA, Ikeda Y. Lentiviral vectors: basic to translational. Biochem J. 2012 May 1;443(3):603–618.
   PubMed Web of Science ®Google Scholar
• Gruber A, Kan-Mitchell J, Kuhen KL, et al. Dendritic cells transduced by multiply deleted HIV-1 vectors exhibit normal phenotypes and functions and elicit an HIV-specific cytotoxic T-lymphocyte response in vitro. Blood. 2000 Aug 15;96(4):1327–1333.
   PubMed Web of Science ®Google Scholar
• Lizee G, Gonzales MI, Topalian SL. Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells. Hum Gene Ther. 2004 Apr;15(4):393–404.
   PubMed Web of Science ®Google Scholar
• Ahmed Ali HA, Di J, Mei W, et al. Antitumor activity of lentivirus-mediated interleukin −12 gene modified dendritic cells in human lung cancer in vitro. Asian Pac J Cancer Prev. 2014;15(2):611–616.
   PubMedGoogle Scholar
• Wilkie S, van Schalkwyk MC, Hobbs S, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol. 2012 Oct;32(5):1059–1070.
   PubMed Web of Science ®Google Scholar
• Song DG, Ye Q, Poussin M, et al. Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level. J Hematol Oncol. 2016 Jul 20;9(1):56.
   PubMed Web of Science ®Google Scholar
• Kim JH, Majumder N, Lin H, et al. Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine. Hum Gene Ther. 2005 Nov;16(11):1255–1266.
   PubMed Web of Science ®Google Scholar
• Albershardt TC, Campbell DJ, Parsons AJ, et al. LV305, a dendritic cell-targeting integration-deficient ZVex(TM)-based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response. Mol Ther Oncolytics. 2016;3:16010.
   PubMed Web of Science ®Google Scholar
• Li S, Wei Q, Li Q, et al. Down-regulating HIF-1alpha by lentivirus-mediated shRNA for therapy of triple negative breast cancer. Cancer Biol Ther. 2015;16(6):866–875.
   PubMed Web of Science ®Google Scholar
• Guo B, Zhang Y, Luo G, et al. Lentivirus-mediated small interfering RNA targeting VEGF-C inhibited tumor lymphangiogenesis and growth in breast carcinoma. Anat Rec. 2009 May;292(5):633–639.
   Google Scholar
• Han Z, Jiang G, Zhang Y, et al. Effects of RNA interference-mediated NRP-1 silencing on the proliferation and apoptosis of breast cancer cells. Mol Med Rep. 2015 Jul;12(1):513–519.
   PubMed Web of Science ®Google Scholar
• Zhao X, Zou Y, Gu Q, et al. Lentiviral vector mediated claudin1 silencing inhibits epithelial to mesenchymal transition in breast cancer cells. Viruses. 2015 Jun 10;7(6):2965–2979.
   PubMed Web of Science ®Google Scholar
• Knezevic J, Pfefferle AD, Petrovic I, et al. Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential. Oncogene. 2015 Dec 3;34(49):5997–6006.
   PubMed Web of Science ®Google Scholar
• Moss B, editor. Poxviridae. Philadelphia: Lippincott Williams & Wilkins; 2013.
   Google Scholar
• McFadden G. Poxvirus tropism. Nat Reviews Microbiol. 2005 Mar;3(3):201–213.
   PubMed Web of Science ®Google Scholar
• Chan WM, McFadden G. Oncolytic poxviruses. ‎Annu Rev Virol. 2014 Sep 1;1(1):119–141.
   PubMed Web of Science ®Google Scholar
• Parato KA, Breitbach CJ, Le Boeuf F, et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Therapy. 2012 Apr;20(4):749–758.
   PubMed Web of Science ®Google Scholar
• Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clinical Practice Oncol. 2007 Feb;4(2):101–117.
   PubMedGoogle Scholar
• Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer. 2009 Jan;9(1):64–71.
   PubMed Web of Science ®Google Scholar
• Bernards R, Destree A, McKenzie S, et al. Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector. Proc Natl Acad Sci USA. 1987 Oct;84(19):6854–6858.
   PubMed Web of Science ®Google Scholar
• Lathe R, Kieny MP, Gerlinger P, et al. Tumour prevention and rejection with recombinant vaccinia. Nature. 1987 Apr 30–May 6;326(6116):878–880.
   PubMed Web of Science ®Google Scholar
• Hareuveni M, Gautier C, Kieny MP, et al. Vaccination against tumor cells expressing breast cancer epithelial tumor antigen. Proc Natl Acad Sci USA. 1990 Dec;87(23):9498–9502.
   PubMed Web of Science ®Google Scholar
• Meneguzzi G, Kieny MP, Lecocq JP, et al. Vaccinia recombinants expressing early bovine papilloma virus (BPV1) proteins: retardation of BPV1 tumour development. Vaccine. 1990 Jun;8(3):199–204.
   PubMed Web of Science ®Google Scholar
• Kaufman H, Schlom J, Kantor J. A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). Int J Cancer. 1991 Jul 30;48(6):900–907.
   PubMed Web of Science ®Google Scholar
• Kantor J, Irvine K, Abrams S, et al. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst. 1992 Jul 15;84(14):1084–1091.
   PubMed Web of Science ®Google Scholar
• Kantor J, Irvine K, Abrams S, et al. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res. 1992 Dec 15;52(24):6917–6925.
   PubMed Web of Science ®Google Scholar
• Arlen PM, Skarupa L, Pazdur M, et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol. 2007 Oct;178(4 Pt 1):1515–1520.
   PubMed Web of Science ®Google Scholar
• Lutz E, Yeo CJ, Lillemoe KD, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation. Ann Surgery. 2011 Feb;253(2):328–335.
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Madan RA, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother. 2010 May;59(5):663–674.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29;363(5):411–422.
   PubMed Web of Science ®Google Scholar
• Gil M, Seshadri M, Komorowski MP, et al. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proc Natl Acad Sci USA. 2013 Apr 02;110(14):E1291–E300.
   PubMed Web of Science ®Google Scholar
• Mohebtash M, Tsang KY, Madan RA, et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res. 2011 Nov 15;17(22):7164–7173.
   PubMed Web of Science ®Google Scholar
• Hodge JW, Chakraborty M, Kudo-Saito C, et al. Multiple costimulatory modalities enhance CTL avidity. J Immunology. 2005 May 15;174(10):5994–6004.
   PubMed Web of Science ®Google Scholar
• Hodge JW, Sabzevari H, Yafal AG, et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 1999 Nov 15;59(22):5800–5807.
   PubMed Web of Science ®Google Scholar
• Hodge JW, Grosenbach DW, Aarts WM, et al. Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res. 2003 May;9(5):1837–1849.
   PubMed Web of Science ®Google Scholar
• Grosenbach DW, Barrientos JC, Schlom J, et al. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res. 2001 Jun 1;61(11):4497–4505.
   PubMed Web of Science ®Google Scholar
• Madan RA, Arlen PM, Gulley JL. PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. Expert Opin Biol Ther. 2007 Apr;7(4):543–554.
   PubMed Web of Science ®Google Scholar
• Madan RA, Arlen PM, Mohebtash M, et al. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs. 2009 Jul;18(7):1001–1011.
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Tsang KY, et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res. 2008 May 15;14(10):3060–3069.
   PubMed Web of Science ®Google Scholar
• Nawa A, Luo C, Zhang L, et al. Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy. Curr Gene Ther. 2008 Jun;8(3):208–221.
   PubMed Web of Science ®Google Scholar
• Todo T. Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front Biosci. 2008 Jan 1;13:2060–2064.
   PubMed Web of Science ®Google Scholar
• Wu A, Mazumder A, Martuza RL, et al. Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation. Cancer Res. 2001 Apr 1;61(7):3009–3015.
   PubMed Web of Science ®Google Scholar
• Shen Y, Nemunaitis J. Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther. 2006 Nov;13(11):975–992.
   PubMed Web of Science ®Google Scholar
• Nakao A, Kimata H, Imai T, et al. Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer. Ann Oncology. 2004 Jun;15(6):988–989.
   PubMed Web of Science ®Google Scholar
• Shimoyama S, Goshima F, Teshigahara O, et al. Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models. Hepato-Gastroenterology. 2007 Jun;54(76):1038–1042.
   PubMedGoogle Scholar
• Teshigahara O, Goshima F, Takao K, et al. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10. J Surg Oncol. 2004 Jan;85(1):42–47.
   PubMed Web of Science ®Google Scholar
• Takakuwa H, Goshima F, Nozawa N, et al. Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. Arch Virol. 2003 Apr;148(4):813–825.
   PubMed Web of Science ®Google Scholar
• Sahin TT, Kasuya H, Nomura N, et al. Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer. Cancer Gene Ther. 2012 Apr;19(4):229–237.
   PubMed Web of Science ®Google Scholar
• Fasullo M, Burch AD, Britton A. Hypoxia enhances the replication of oncolytic herpes simplex virus in p53- breast cancer cells. Cell Cycle. 2009 Jul 15;8(14):2194–2197.
   PubMed Web of Science ®Google Scholar
• Hsu CR, Lu TM, Chin LW, et al. Possible DNA viral factors of human breast cancer. Cancers. 2010 Apr 13;2(2):498–512.
   PubMedGoogle Scholar
• Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Therapy. 2003 Feb;10(4):292–303.
   PubMed Web of Science ®Google Scholar
• Gong J, Sachdev E, Mita AC, et al. Clinical development of reovirus for cancer therapy: an oncolytic virus with immune-mediated antitumor activity. World J Methodol. 2016 Mar 26;6(1):25–42.
   PubMedGoogle Scholar
• Gollamudi R, Ghalib MH, Desai KK, et al. Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs. 2010 Oct;28(5):641–649.
   PubMed Web of Science ®Google Scholar
• Morris DG, Feng X, DiFrancesco LM, et al. REO-001: a phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin(R)) in patients with advanced solid tumors. Invest New Drugs. 2013 Jun;31(3):696–706.
   PubMed Web of Science ®Google Scholar
• Lolkema MP, Arkenau HT, Harrington K, et al. A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res. 2011 Feb 01;17(3):581–588.
   PubMed Web of Science ®Google Scholar
• Clements D, Helson E, Gujar SA, et al. Reovirus in cancer therapy: an evidence-based review. Oncolytic Virotherapy. 2014;3:69–82.
   PubMedGoogle Scholar
• Thirukkumaran C, Morris DG. Oncolytic viral therapy using reovirus. Methods Mol Biol. 2009;542:607–634.
   PubMedGoogle Scholar
• Norman K, Coffey CM, Hirasawa K, et al. Reovirus oncolysis of human breast cancer. Hum Gene Ther. 2004 Jul;13(5):641–652.
   Web of Science ®Google Scholar
• Pidre ML, Ferrelli ML, Haase S, et al. Baculovirus display: a novel tool for vaccination. In: Victor Romanowski, editor. Current Issues in Molecular Virology. Viral Genetics and Biotechnological Applications. InTech. Croatia 2013.
   Google Scholar
• Paul A, Jardin BA, Kulamarva A, et al. Recombinant baculovirus as a highly potent vector for gene therapy of human colorectal carcinoma: molecular cloning, expression, and in vitro characterization. Mol Biotechnol. 2010 Jun;45(2):129–139.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Oo Chang M, Kitajima M, et al. Induction of antitumor immunity against mouse carcinoma by baculovirus-infected dendritic cells. Cell Mol Immunol. 2010 Nov;7(6):440–446.
   PubMed Web of Science ®Google Scholar
• Kawahara M, Takaku H. Intradermal immunization with combined baculovirus and tumor cell lysate induces effective antitumor immunity in mice. Int J Oncol. 2013 Dec;43(6):2023–2030.
   PubMed Web of Science ®Google Scholar
• Lesch HP, Makkonen KE, Laitinen A, et al. Requirements for baculoviruses for clinical gene therapy applications. J Invertebr Pathol. 2011 Jul;107(Suppl):S106–12.
   PubMed Web of Science ®Google Scholar
• Schirrmacher V, Fournier P. Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer. Methods Mol Biol. 2009;542:565–605.
   PubMedGoogle Scholar
• Ahmad U, Ahmed I, Keong YY, et al. Inhibitory and apoptosis-inducing effects of Newcastle disease virus strain AF2240 on mammary carcinoma cell line. Biomed Res Int. 2015;2015:127828.
   PubMed Web of Science ®Google Scholar
• Zamarin D, Palese P. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol. 2012 Mar;7(3):347–367.
   PubMed Web of Science ®Google Scholar
• Alkayyal AA, Mahmoud AB, Auer RC. Interleukin-12-expressing oncolytic virus: a promising strategy for cancer immunotherapy. J Taibah Univ Med Sci. 2016 April;11(3):187–193.
   Google Scholar
• Swaminathan S. Of Newcastle disease virus AF2240 on allografted 4T1 breast cancer cells in BALB/c mice. Malaysia:Universiti Putra Malaysia-;  2010.
   Google Scholar
• Othman F, Ideris A, Motalleb G, et al. Oncolytic effect of Newcastle disease virus AF2240 strain on the MCF-7 breast cancer cell line. Yakhteh Med J. 2010;12(1):17–24.
   Google Scholar
• Omar AR, Ideris A, Ali AM, et al. An overview on the development of Newcastle disease virus as an anti-cancer therapy. Malays J Med Sci. 2003 Jan;10(1):4–12.
   PubMedGoogle Scholar
• Motalleb G, Othman F, Ideris A, et al. Dissemination of Newcastle disease virus (NDV-AF2240) in liver during intratumoral injection of xenotransplant breast cancer in BALB/c mice. Yakhteh Med J. 2009;11(3):303–310.
   Google Scholar
• Bai L, Koopmann J, Fiola C, et al. Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients. Int J Oncol. 2002 Oct;21(4):685–694.
   PubMed Web of Science ®Google Scholar
• Ahlert T, Sauerbrei W, Bastert G, et al. Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer. J Clin Oncol. 1997 Apr;15(4):1354–1366.
   PubMed Web of Science ®Google Scholar
• Gonin P, Gaillard C. Gene transfer vector biodistribution: pivotal safety studies in clinical gene therapy development. Gene Ther. 2004 Oct;11(Suppl 1):S98–S108.
   PubMed Web of Science ®Google Scholar
• Fumoto S, Kawakami S, Hashida M, et al. Targeted gene delivery: importance of administration routes. In: Ming Wei and David Good, editors. Novel Gene Therapy Approaches. InTech. Croatia 2013.
   Google Scholar
• Xu Z, Tian J, Smith JS, et al. Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J Virol. 2008 Dec;82(23):11705–11713.
   PubMed Web of Science ®Google Scholar
• Ahi YS, Bangari DS, Mittal SK. Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther. 2011 Aug;11(4):307–320.
   PubMed Web of Science ®Google Scholar
• Haisma HJ, Kamps JA, Kamps GK, et al. Polyinosinic acid enhances delivery of adenovirus vectors in vivo by preventing sequestration in liver macrophages. J Gen Virol. 2008 May;89(Pt 5):1097–1105.
   PubMed Web of Science ®Google Scholar
• Zhu W, Zhang H, Shi Y, et al. Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer. Cancer Biol Ther. 2013 Nov;14(11):1016–1023.
   PubMed Web of Science ®Google Scholar
• Willmon C, Harrington K, Kottke T, et al. Cell carriers for oncolytic viruses: fed Ex for cancer therapy. Mol Therapy. 2009 Oct;17(10):1667–1676.
   PubMed Web of Science ®Google Scholar
• Bazan-Peregrino M, Sainson RC, Carlisle RC, et al. Combining virotherapy and angiotherapy for the treatment of breast cancer. Cancer Gene Ther. 2013 Aug;20(8):461–468.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Hu Z, Gupta J, et al. Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host. Cancer Gene Ther. 2012 Sep;19(9):630–636.
   PubMed Web of Science ®Google Scholar
• Cody JJ, Rivera AA, Lyons GR, et al. Arming a replicating adenovirus with osteoprotegerin reduces the tumor burden in a murine model of osteolytic bone metastases of breast cancer. Cancer Gene Ther. 2010 Dec;17(12):893–905.
   PubMed Web of Science ®Google Scholar
• Xiao W, Chirmule N, Schnell MA, et al. Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors. Mol Ther. 2000 Apr;1(4):323–329.
   PubMed Web of Science ®Google Scholar
• Marodon G, Mouly E, Blair EJ, et al. Specific transgene expression in human and mouse CD4+ cells using lentiviral vectors with regulatory sequences from the CD4 gene. Blood. 2003 May 1;101(9):3416–3423.
   PubMed Web of Science ®Google Scholar
• Moreau T, Bardin F, Imbert J, et al. Restriction of transgene expression to the B-lymphoid progeny of human lentivirally transduced CD34+ cells. Mol Therapy. 2004 Jul;10(1):45–56.
   PubMed Web of Science ®Google Scholar
• Laurie KL, Blundell MP, Baxendale HE, et al. Cell-specific and efficient expression in mouse and human B cells by a novel hybrid immunoglobulin promoter in a lentiviral vector. Gene Therapy. 2007 Dec;14(23):1623–1631.
   PubMed Web of Science ®Google Scholar
• Uhlig KM, Schulke S, Scheuplein VA, et al. Lentiviral protein transfer vectors are an efficient vaccine platform and induce a strong antigen-specific cytotoxic T cell response. J Virol. 2015 Sep;89(17):9044–9060.
   PubMed Web of Science ®Google Scholar
• Cire S, Da Rocha S, Yao R, et al. Immunization of mice with lentiviral vectors targeted to MHC class II+ cells is due to preferential transduction of dendritic cells in vivo. PLoS One. 2014;9(7):e101644.
   PubMed Web of Science ®Google Scholar
• Miller AC, Russell SJ. Heterogeneous delivery is a barrier to the translational advancement of oncolytic virotherapy for treating solid tumors. Virus Adapt Treat. 2014;6(1):11–31.
   Google Scholar
• Mittapalli RK, Adkins CE, Bohn KA, et al. Quantitative fluorescence microscopy measures vascular pore size in primary and metastatic brain tumors. Cancer Res. 2017 Jan 15;77(2):238–246.
   PubMed Web of Science ®Google Scholar
• Ahmed AU, Alexiades NG, Lesniak MS. The use of neural stem cells in cancer gene therapy: predicting the path to the clinic. Curr Opin Mol Ther. 2010 Oct;12(5):546–552.
   PubMed Web of Science ®Google Scholar
• Li Z, Fan D, Xiong D. Mesenchymal stem cells as delivery vectors for anti-tumor therapy. Stem Cell Investig. 2015;2:6.
   PubMedGoogle Scholar
• Aboody KS, Najbauer J, Danks MK. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther. 2008 May;15(10):739–752.
   PubMed Web of Science ®Google Scholar
• Zhao D, Najbauer J, Annala AJ, et al. Human neural stem cell tropism to metastatic breast cancer. Stem Cells. 2012 Feb;30(2):314–325.
   PubMed Web of Science ®Google Scholar
• Joo KM, Park IH, Shin JY, et al. Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases. Mol Ther. 2009 Mar;17(3):570–575.
   PubMed Web of Science ®Google Scholar
• Yi BR, Hwang KA, Aboody KS, et al. Selective antitumor effect of neural stem cells expressing cytosine deaminase and interferon-beta against ductal breast cancer cells in cellular and xenograft models. Stem Cell Res. 2014 Jan;12(1):36–48.
   PubMed Web of Science ®Google Scholar
• Xia X, Ji T, Chen P, et al. Mesenchymal stem cells as carriers and amplifiers in CRAd delivery to tumors. Mol Cancer. 2011 Nov;03(10):134.
   Web of Science ®Google Scholar
• Stoff-Khalili MA, Rivera AA, Mathis JM, et al. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat. 2007 Oct;105(2):157–167.
   PubMed Web of Science ®Google Scholar
• Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007 Oct 4;449(7162):557–563.
   PubMed Web of Science ®Google Scholar
• Amariglio N, Hirshberg A, Scheithauer BW, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 2009 Feb 17;6(2):e1000029.
   PubMed Web of Science ®Google Scholar
• Qiao L, Xu ZL, Zhao TJ, et al. Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Lett. 2008 Sep 28;269(1):67–77.
   PubMed Web of Science ®Google Scholar
• Ramos CA, Asgari Z, Liu E, et al. An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. Stem Cells. 2010 Jun;28(6):1107–1115.
   PubMed Web of Science ®Google Scholar
• Martinez-Quintanilla J, Bhere D, Heidari P, et al. Therapeutic efficacy and fate of bimodal engineered stem cells in malignant brain tumors. Stem Cells. 2013 Aug;31(8):1706–1714.
   PubMed Web of Science ®Google Scholar